Call for Abstracts
Important Information
- Submission deadline:
March 18, 2024 @ 23:59 EST.
Extended to April 5, 2024 @ 23:59 EST. - Notification of acceptance: June 03, 2024.
- Registration: presenters must be registered and have paid the registration fee by June 17, 2024; otherwise, the abstract will be removed from the program.
- ONLY accepted abstracts by a presenter registered to attend the Congress will be published in an online supplement of the Transplantation Journal.
- It is the submitter responsibility to ensure that all co-authors approve of the abstract submission, publication, and potential presentation at TTS 2024.
Please read the instructions before accessing the submission page.
Abstract Submission Process
During the submission process, you will be asked to select 3 tiers of general topics for your abstracts to help us with the review and assignment process.
- Tier 1: General topics*
- Tier 2: Congress theme*
- Tier 3: Main keywords
* See lists further below.
Abstracts must be comprised of four distinct sections:
- Introduction: Describes previous research and the rationale for the current study
- Method: Describes how the study was conducted
- Results: Describes the results of the study
- Conclusion: Summarize the study and discusses its implications
Please do not insert tables into the body of the abstracts. They will need to be uploaded into jpg, png or gif as a figure.
All abstracts must be submitted electronically through the Congress management system.
- Abstracts should be submitted only in English and there is no fee for submission.
- The abstract has a limit of 10 authors and affiliation entry. If your research involved more than 10 authors we would suggest that you enter further details into the study group list and only limit the list to those that were primary involved in the research.
- The abstract text body is limited to 3,000 characters including spaces (about 400 words or more, depending on spacing). A maximum of two figures (in JPG, GIF or PNG with ideally 600 dpi) can be included. These will not count toward the word limit, nor will the information about authors, institutions and study groups. File size of 2 MB maximum for each figure. Make sure you submit your figure with no surrounding white space and the text is readable.
- By submitting an abstract to TTS 2024, the submitter consent to having the abstract, if accepted, published in the online supplement of the Transplantation Journal as well as in the Congress website.
- Only registered presenters will have their accepted abstracts published.
- It is the submitter responsibility to ensure that all co-authors approve of the abstract submission, publication, and potential presentation at TTS 2024.
- Presenters from employees of commercial interests, selected for an oral or a poster presentation, may be required to submit additional information, including the presentation slides. Presenting content featuring clinical recommendations aligned to the business interests and/or products of the employer is strictly prohibited.
Policies for Abstract Submission
Abstracts should not include libelous or defamatory content. Material presented in abstracts should not violate any copyright laws. If figures/graphics/images have been taken from sources not copyrighted by the author, it is the author’s sole responsibility to secure the rights from the copyright holder in writing to reproduce those figures/graphics/images for both worldwide print and web publication. All reproduction costs charged by the copyright holder must be borne by the author.
TTS 2024 welcomes the submission of abstracts previously presented at national, regional or international meetings in the two years preceding the congress. Encores must be documented as such at the time of submission. To be accepted, the abstract must include significant additional data from the previous presentation/s. Submission will not be permitted if a manuscript has been published.
TTS 2024 regard plagiarism as serious professional misconduct. All abstracts are screened for plagiarism and when identified, the abstract and any other abstracts submitted by the same author will be rejected. In addition, the submitting author’s profile and scholarship application, in the case one has been submitted, will also be cancelled.
To be eligible to submit an abstract, you must disclose that the author(s)/ scientist(s) have not violated any aspect of the following Ethics Statement:
- Declaration of Istanbul (DOI) ethics' statement
- Research conforms with the ethical statement on human research subject, Helsinki Declaration of The World Medical Association
- The Ethics of Xenotransplantation (Xenotransplantation 10:194-203, 2003) For research involving human subjects -The Helsinki.
- The Transplantation Society Ethics statement
Abstract Review and Selection Process
- All submitted abstracts will go through blind peer-review carried out by an international committee
- All abstracts will be reviewed by at least three international referees selected by the Scientific Program Committee
- Abstracts which do not meet the focus of the topic selected by the authors will be reassigned at the discretion of the Review Committee
- Abstracts will be assessed based the following criteria:
- Interest: Is the content original/important/relevant to our field?
- Novelty: How and to what extent are the findings likely to influence clinical or research practice, education or policy?
- Robustness and quality of the data: Are the methods/ methodological approach clearly described? How confident is the reviewer in the strength/trustworthiness of the data and/or conclusions/discussion presented?
- Presentation and Clarity: The basic purpose of the research/project is clear
Abstracts may be submitted for either oral, poster, or oral/poster presentation (to be determined at the Committee’s discretion). Please note that space is very limited for oral abstract presentations.
Each presenting author may present a maximum of one oral abstract at the congress: one oral OR one oral and 1 poster OR 2 posters. The number of submissions is however not limited. Should an author have more than one oral abstract accepted, a co-author must be named as presenting author for one or more abstracts.
Congress Themes
Big Data |
Cellular therapies/immunotherapies/novel experimental therapies |
Education and patient-centred care |
Equity, intersectionality and access to transplantation |
Green growth and environmental sustainability and transplantation |
Life participation and living well after transplantation |
Novel intervention - trials/ novel trial designs |
Organ donation, allocation and utilisation |
Organ perfusion and preservation |
Pancreas and Islet |
Policies, implementation, dissemination |
Precision medicine |
Problem solving, dealing with post-transplant complications |
Regenerative medicine |
Reproductive care |
Tolerance |
Transformational learning - learning from failures/patient safety |
Xenotransplantation and reconstructive transplantation |
Abstract Topics
Some topics have sub-topics, not all.
- Allied Health
- Nurses, nutrition, pharmacist, psychology, therapist, etc.
- Basic and Translational Sciences
- B cells/antibody
- Biologics/co-stimulation blockade
- Biomarkers
- Cell signalling
- Data science
- First-in-human trials
- Immunosuppression minimisation
- Infection
- IRI/preconditioning
- Novel therapeutics
- Omics - transciptomcs, genomics, radiomics, spatial, single cell, metabolomics
- Rejection mechanisms
- Tolerance
- Other
- Cell Transplantation
- Cell Transplantation Topics
- Clinical trials (late-breaking trials)
- Clinical trials (late-breaking trials) Topics
- Education / Training
- Education / Training Topics
- Ethics, Policies, Health economics and Trafficking
- Ethics, Policies, Health economics and Trafficking Topics
- Histocompatibility & ABOi
- Histocompatibility & ABOi Topics
- Infectious Diseases / Covid
- Bacterial infections
- Covid related topics
- Covid-19 and donation
- Disease transmission
- Fungal infections
- Viral infections
- Other
- Kidney
- ABO incompatible
- Acute Kidney Injury
- Ageing and Kidney Transplantation
- Antibody Mediated Rejection
- Diagnostics
- Eplet and prediction
- HLA
- Kidney Deceased Donor Issues (DCD, ECD/SCD)
- Living donor transplants
- Malignancies
- Metabolic complications
- Mixed rejection
- Outcomes
- Pre-transplant managment
- Recipient Selelection
- Recurrent diseases
- Rejections
- Surgical
- Surgical complications
- T cell mediated rejection
- Other
- Liver / Intestinal
- Complications
- Intestine multivisceral
- Liver Failure
- Living donor transplants
- Long-term follow up
- Malignancies hepatocellular and cholangiocarcinoma
- Recipient selection/Management
- Recurrent diseases
- Rejection
- Small bowel multivisceral
- Split transplantation/Partial grafts
- Surgical
- Tolerance
- Other
- Multi-Organ (liver/kidney, kidney/pancreas, etc.)
- Multi-Organ (liver/kidney, kidney/pancreas, etc.) Topics
- Organ Donation / Critical Care
- Allocation
- Anesthesia management
- Critical care management
- DCD
- Living donation
- Preservation/perfusion
- Procurement
- Recipient selection / Contraindications to transplant
- Utilization
- Other
- Pancreas & Islet
- Pancreas
- Islet
- Other
- Registry (Prediction, machine learning, artifical intelligenece)
- Registry (Prediction, machine learning, artifical intelligenece) Topics
- Pediatrics
- Pediatrics Topics
- Regenerative Medicine/Bioengineering
- Regenerative Medicine/Bioengineering Topics
- Sex, Gender and Sexuality
- Sex, Gender and Sexuality Topics
- Surgical Techniques (Video submissions)
- Surgical Techniques (Video submissions) Topics
- Thoracic (Heart and Lung)
- Heart
- Lung
- Thoracic
- Transplant Complications
- Transplant Complications Topics
- Transplant Immunossupression
- Complications of IS
- Kidney Immunosuppression
- Personalized immunosuppression/ Pharmacogenomics/pharmacokinetics
- Tolerance
- Induction Therapy
- Novel agents
- Other
- VCA / Uterus
- VCA / Uterus Topics
- Xenotransplantation
- Xenotransplantation Topics
- Others
- Others Topics